**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 72516

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma**

Mohamed GA *et al*. FGF-19 as a non-invasive marker for HCC

Ghada Abdelrahman Mohamed, Ehab Hasan Nashaat, Hadeer Mohamed Fawzy, Ahmed Mohamed ElGhandour

**Ghada Abdelrahman Mohamed, Ehab Hasan Nashaat, Hadeer Mohamed Fawzy, Ahmed Mohamed ElGhandour,** Department of Internal Medicine, Gastroenterology and Hepatology Unit, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt

**Author contributions:** Mohamed GA, Nashaat EH, and ElGhandour AM designed the study; Fawzy HM participated in the acquisition of the data; Mohamed GA, Nashaat EH, Fawzy HM, and ElGhandour AM participated in the analysis and interpretation of the data; Mohamed GA, Nashaat EH, Fawzy HM, and ElGhandour AM revised the article critically for important intellectual content; Mohamed GA wrote the manuscript.

**Corresponding author: Ghada Abdelrahman Mohamed, MD, Lecturer,** Department of Internal Medicine, Gastroenterology and Hepatology Unit, Faculty of Medicine, Ain Shams University, El Khalifa El-Maamon St., Abbassia, Cairo 11591, Egypt. ghadaabdelrahman@med.asu.edu.eg

**Received:** October 19, 2021

**Revised:** December 19, 2022

**Accepted:** February 20, 2022

**Published online:** March 27, 2022

**Abstract**

BACKGROUND

Fibroblast growth factor 19 (FGF-19) is one of the founding members of the endocrine FGF subfamily. Recently, it has been the subject of much interest owing to its role in various physiological processes affecting glucose and lipid metabolism and the regulation of bile acid secretion as well as cell proliferation, differentiation, and motility. Additionally, FGF-19 secretion in an autocrine style has reportedly contributed to cancer progression in various types of malignancies including hepatocellular carcinoma (HCC).

AIM

To estimate the serum FGF-19 concentrations in HCC cases and assess its diagnostic performance for the detection of HCC.

METHODS

We recruited 90 adult participants and divided them into three equal groups: Healthy controls, cirrhosis patients, and HCC patients. Serum FGF-19 concentrations were measured using the Human FGF-19 ELISA kit.

RESULTS

We detected a high statistically significant difference in serum FGF-19 levels among the three groups. The highest level was observed in the HCC group, followed by the cirrhosis and control groups (236.44 ± 40.94 *vs* 125.63 ± 31.54 *vs* 69.60 ± 20.90 pg/mL, respectively, *P* ≤ 0.001). FGF-19 was positively correlated with alpha fetoprotein (AFP; *r* = 0.383, *P* = 0.003) and international normalised ratio (*r* = 0.357, *P* = 0.005), while it was negatively correlated with albumin (*r* = -0.500, *P* ≤ 0.001). For the detection of HCC, receiver operating characteristic curve analysis showed that the best cut-off point of AFP was > 8.2 ng/mL with an area under the curve (AUC) of 0.78, sensitivity of 63.33%, specificity of 83.33%, positive predictive value (PPV) of 79.2%, negative predictive value (NPV) of 69.4%, and total accuracy of 78%. However, FGF-19 at a cut-off point > 180 pg/mL had an AUC of 0.98, sensitivity of 100%, specificity of 90.0%, PPV of 90.0%, NPV of 100%, and total accuracy of 98%.

CONCLUSION

FGF-19 represents a possible novel non-invasive marker for HCC. It may improve the prognosis of HCC patients due to its utility in several aspects of HCC detection and management.

**Key Words:** Fibroblast growth factor 19; FGF-19; Fibroblast growth factors; Tumour biomarkers; Hepatocellular carcinoma; Detection; Cirrhosis

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Mohamed GA, Nashaat EH, Fawzy HM, ElGhandour AM. Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma. *World J Hepatol* 2022; 14(3): 623-633

**URL:** https://www.wjgnet.com/1948-5182/full/v14/i3/623.htm

**DOI:** https://dx.doi.org/10.4254/wjh.v14.i3.623

**Core Tip:** We recruited 90 adult participants and divided them into three equal groups: Healthy controls, cirrhosis patients, and hepatocellular carcinoma (HCC) patients. We detected a high statistically significant difference in fibroblast growth factor 19 (FGF-19) levels among the three groups, with the highest level occurring in the HCC group, followed by the cirrhosis and control groups (236.44 ± 40.94 *vs* 125.63 ± 31.54 *vs* 69.60 ± 20.90 pg/mL, respectively, *P* ≤ 0.001). For the detection of HCC, receiver operating characteristic curve analysis showed that FGF-19 demonstrated a better diagnostic performance than alpha fetoprotein (area under the curve = 0.98 *vs* 0.78). Consequently, we can conclude that FGF-19 represents a possible novel non-invasive marker for HCC.

**INTRODUCTION**

Fibroblast growth factor 19 (FGF-19) is one of the founding members of the endocrine FGF subfamily[1]. Recently, it has been the subject of much interest owing to its role in various physiological processes affecting glucose and lipid metabolism and bile acid secretion as well as cell proliferation, differentiation, and motility[2-4]. Additionally, FGF-19 secretion in an autocrine style has reportedly contributed to cancer progression in various types of malignancies including hepatocellular carcinoma (HCC)[5-9].

FGF-19 has a restricted pattern of expression. It is mostly expressed in the terminal ileum in response to the bile-acid-stimulated intestinal Farnesoid X receptor (FXR)[10], and then, through the portal circulation to the liver, it attaches to its receptor, fibroblast growth factor receptor 4 (FGFR4), and a co-factor known as β-klotho. This action initiates the transcription of various genes that negatively regulate bile acid synthesis through the downregulation of CYP7A1[11].

Although FGF-19 is formed principally in the ileum and FGF-19 expression is almost absent in the human liver under normal conditions, current studies propose that FGF-19 may be autocrined by human hepatocytes under cholestatic conditions, peritumoral tissue cirrhosis, and HCC. The secretion of FGF-19 in these conditions demonstrates the protective negative feedback of FGF-19 in order to guard hepatocytes from the cytotoxicity of bile acids[12-14] and the promotion of the development and progression of HCC by bile acids through mTOR dependent mechanisms[15]. This beneficial effect of the FGF-19 pathway has also been proposed in other studies in *FXR*-/-knock out mice that developed hepatic malignancies, which were inhibited by the expression of an *FXR* transgene in the intestine[16]. This effect indicates the protective aspect of Fgf15 (the mouse homolog of human FGF-19) in relation to hepatic malignancies. Additionally, Fgf15/FGF19 mediated hepatic regeneration in mice in other studies[17,18].

However, the higher expression of FGF-19 in HCC patients has been found to promote tumour cell survival and has antiapoptotic impacts that are applied through the FGFR4-glycogen synthase kinase (GSK)3β-Nrf2 signalling pathway[19]. Moreover, Kang *et al*[20] showed that a distinctive molecular subtype of FGF-19 is correlated with a poor prognosis in HCC patients. In addition, Cui *et al*[21] and Zhao *et al*[22] reported that Fgf15 and FGF-19, respectively, promoted the progression of HCC by stimulating epithelial-mesenchymal transition and Wnt/β-catenin cascade, which is linked to tumour aggression and mortality. Furthermore, previous data has pointed to FGF-19 as a promoter of liver stem cells in HCC patients, as noted in the robust association between FGF-19 and EpCAM, which is a moderator of cell adhesion and signalling and a special biomarker for liver cancer stem cells[23,24]. Additionally, confirmation of the role of FGF-19 signalling in HCC progression arises from the tumour-preventing effect of the selective FGFR4 inhibitor BLU9931 in a mouse HCC model with implanted FGF-19-producing, FGFR4-expressing hepatic cells[25]. These results suggest that FGF-19 may be implicated in tumour development in HCC cases.

Since FGF-19 is a serum protein secreted by HCC cells in an autocrine loop style, and systemic concentrations of FGF-19 have been found to reflect its portal concentrations[14,26], we aimed to estimate the serum FGF-19 concentrations in HCC cases and assess the diagnostic performance of FGF-19 for the detection of HCC.

**MATERIALS AND METHODS**

This observational study was conducted at Ain Shams University Hospitals in Cairo, Egypt from March 2021 to September 2021. This study was performed in accordance with the ethics principles of the Declaration of Helsinki and was authorised by the ethics board of the Faculty of Medicine, Ain Shams University (No. FMASU MS 66/2021). Written informed approval was obtained from all the participants before they were enrolled in the study.

We consecutively recruited 90 adult participants and divided them into three equal groups: Healthy controls, cirrhosis patients, and HCC patients. Patients with any malignant disease other than HCC were excluded. None of the HCC cases had either neoadjuvant chemotherapy or radiotherapy.

***Diagnosis of cirrhosis and HCC***

Cirrhosis was diagnosed according to laboratory parameters, clinical manifestations, and/or histological criteria[27]. HCC was identified through contrast-enhanced imaging studies and/or histological criteria as per the practice guidelines[28].

***Measurement of serum FGF-19 concentrations***

The serum FGF-19 concentrations were measured using the Human FGF-19 ELISA kit (SunRed Biological Technology Co. Ltd., Shanghai, China, Catalogue # 201-12-2199) with a sensitivity of 2.032 pg/mL, assay range of 2.5-700 pg/mL, intra-assay coefficient of variability (CV) < 10%, and inter-assay CV < 12%.

***Statistical methods***

Data were analysed using the Statistical Package for Social Science (IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp). The qualitative variables are shown as numbers and percentages, while the quantitative variables are shown as the mean, standard deviation, or median and interquartile range, as appropriate. The differences among the groups were calculated using the Chi-square test, Fisher exact test, independent *t*-test, one-way ANOVA test, or Kruskal-Wallis test, as appropriate. A receiver operating characteristic (ROC) curve analysis was applied to assess the diagnostic performance of FGF-19 and alpha fetoprotein (AFP) for HCC detection. A *P* value of less than 0.05 was considered statistically significant.

**RESULTS**

This study included 90 participants divided into control, cirrhosis, and HCC groups. The HCC group was comprised of 19 males (63.3%) and 11 females (36.7%), with a mean age of 57.37 years. In the cirrhotic group, there were 20 males (66.7%) and 10 (33.3%) females, with a mean age of 53.57 years. The control group included 18 males (60%) and 12 females (40%), with a mean age of 51.07 years (Table 1). According to the Child-Pugh class, 14 of the HCC cases (46.7%) belonged to Class C, while 18 (60%) of the cirrhotic cases belonged to Class A (*P* = 0.002, Table 1). There were statistically significant differences among the three groups concerning AFP, haemoglobin, platelets, alanine aminotransferase, aspartate aminotransferase (AST), albumin, international normalised ratio (INR), fasting blood glucose, and bilirubin (Table 1).

We detected a high statistically significant difference in the FGF-19 levels of the three groups. The highest level occurred in the HCC group, followed by the cirrhosis and control groups (236.44 ± 40.94 *vs* 125.63 ± 31.54 *vs* 69.60 ± 20.90 pg/mL, respectively, *P* ≤ 0.001; Table 1, Figure 1). There were seven HCC patients with negative AFP; however, they had elevated FGF-19 levels (> 180 pg/mL). Serum FGF-19 levels were not significantly different according to the Child–Pugh class in the cirrhosis and HCC groups (Table 2).

The tumour characteristics of the HCC cases are shown in Table 3. Serum FGF-19 levels were higher in relation to the size of the tumour, the presence of portal vein thrombosis, jaundice, lower limb oedema, and weight loss; however, these differences did not reach statistical significance (Table 4). FGF-19 was positively correlated with AFP (*r* = 0.383, *P* = 0.003) and INR (*r* = 0.357, *P* = 0.005), while it was negatively correlated with albumin (*r* = -0.500, *P* ≤ 0.001; Table 5, Figure 2).

For the detection of HCC, the ROC curve analysis showed that the best cut-off point of AFP was > 8.2 ng/mL with an area under the curve (AUC) of 0.78, sensitivity of 63.33%, specificity of 83.33%, positive predictive value (PPV) of 79.2%, negative predictive value (NPV) of 69.4%, and total accuracy of 78%. However, FGF-19 at a cut-off point > 180 pg/mL had an AUC of 0.98, sensitivity of 100%, specificity of 90.0%, PPV of 90.0%, NPV of 100%, and total accuracy of 98% (Table 6, Figure 3).

**DISCUSSION**

HCC is the third highest cause of tumour death globally, with a 5-year survival rate of approximately 20% despite the developments in imaging technologies and therapeutic methodologies[29]. Unfortunately, the majority of HCC patients are diagnosed at an advanced stage of disease; therefore, early recognition of the disease is crucial to improving the prognosis and overall survival of patients[24].

Tumour markers have commonly been utilised for numerous objectives, such as diagnosis, follow-up care after treatment, optimisation of therapeutic effectiveness, and prediction of prognosis. Earlier studies have identified various serum markers for HCC which can be applied as diagnostic and prognostic markers for HCC. Although the assessment of these biomarkers is not essential for establishing a conclusive diagnosis of HCC as per the guidelines, these biomarkers play a key role in HCC diagnosis and monitoring[28,30,31]. However, it has been found that AFP, which is the most studied marker, may remain in the normal range not only in the early stages, but also in the advanced stages of HCC[32]. Moreover, an increase of AFP is occasionally detected in cirrhotic patients. Considering these two facts, alternative serum markers with high levels of sensitivity and specificity are needed.

It has previously been reported that FGF-19 may be associated with the pathogenesis and clinical characteristics of HCC[12,24]. Thus, we aimed to investigate the diagnostic utility of FGF-19 in HCC cases. We observed significantly higher serum FGF-19 levels in the HCC group compared to the control and cirrhosis groups. Serum FGF-19 levels were also higher in relation to the size of the tumour and presence of portal vein thrombosis; however, these differences did not reach statistical significance owing to the small sample size.

In accordance with our results, Maeda *et al*[12] detected higher serum levels of FGF-19 in their HCC group (214.5 pg/mL) compared to the cirrhosis group (100.1 pg/mL, *P* < 0.001) and the control group (78.8 pg/mL, *P* = 0.002). However, no statistically significant difference was detected between the cirrhotic cases and controls in their study.

Similar to the current results, Li *et al*[24] detected significantly higher serum FGF-19 levels in the HCC group compared to the control group (145.57 ± 118.72 *vs* 90.18 ± 13.88 pg/mL, *P* = 0.044). They also reported that FGF-19 levels were significantly raised in the HCC tissues (57.80 ± 4.39 pg/10 mg total protein) in comparison to both healthy control tissues (33.29 ± 1.53 pg/10 mg total protein, *P* < 0.001) and paired peritumoral tissues (46.33 ± 2.53 pg/10 mg total protein, *P* = 0.032). Additionally, *FGF-19* mRNA expression was significantly raised in the HCC tissues in comparison to paired peritumoral tissues (3.30 ± 1.82 *vs* 2.25 ± 0.82, respectively, *P* = 0.025).Moreover, FGF-19 expression increased significantly with a strong positive correlation (*r* = 0.968) consistent with the histological severity of hepatic disease, showing a trend in samples with steatosis (224.13 ± 115.68, *P* = 0.087), steatohepatitis (413.99 ± 159.55, *P* = 0.002), cirrhosis (613.35 ± 157.29, *P* < 0.001), and HCC (2507.28 ± 831.10, *P* = 0.001) in comparison to the paired peritumoral tissues (142.96 ± 41.32).

Our results are also consistent with those of Sun *et al*[33], who detected higher FGF-19 levels in the HCC and diabetes-HCC groups than in the control and diabetes groups (220.5, 185.1, 115.8, and 70.4 pg/mL, respectively, *P* < 0.001). All these results indicate that FGF-19 may have a role in the pathogenesis of HCC.

In line with the results of the current research, Sun *et al*[33] detected a positive association between FGF-19 and AFP in HCC patients (*P* < 0.05). However, Maeda *et al*[12] found no significant association between serum FGF-19 concentrations and AFP. Moreover, in partial agreement with the present study, Wunsch *et al*[34] observed that serum and hepatic concentrations of FGF-19 were associated with the severity of hepatic disease, as measured by laboratory parametersincluding albumin (*r* = -0.408, *P* = 0.007), haemoglobin (*r* = -0.394, *P* = 0.01), AST (*r* = 0.328, *P* = 0.03), and total bilirubin (*r* = 0.577, *P* < 0.001).

For HCC detection, in the study by Maeda *et al*[12], the ROC curve analysis determined a cut-off point of FGF-19 of 200 pg/mL, which had an AUC of 0.795, sensitivity of 53.2%, specificity of 95.1%, PPV of 95.9%, and NPV of 48.7%. This result was comparable to those of AFP (AUC = 0.827). However, in the current study, FGF-19 had a better diagnostic performance at a cut-off > 180 pg/mL with an AUC of 0.98, sensitivity of 100%, specificity of 90%, PPV of 90%, and NPV of 100%.

The current study was limited by a small sample size and a high ratio of patients with advanced HCC. Further studies are needed to investigate the clinical applications of the current results. FGF-19 could serve as a predictor of prognosis and a marker for follow-up after HCC treatment. Additionally, the FGF-19 pathway has received increased interest as a possible therapeutic target in chronic liver diseases[5,35-37]. In fact, anti-FGF-19 antibody therapy has been described as inhibiting HCC evolution in FGF-19 transgenic mice[38].

**CONCLUSION**

FGF-19 could be a possible novel non-invasive marker for HCC. It may improve the prognosis of HCC patients due to its utility in several aspects of HCC detection and management.

**ARTICLE HIGHLIGHTS**

***Research background***

Fibroblast growth factor 19 (FGF-19) is one of the founding members of the endocrine FGF subfamily. Recently, it has been the subject of much interest owing to its role in various physiological processes affecting glucose and lipid metabolism and bile acid secretion as well as cell proliferation, differentiation, and motility. Additionally, FGF-19 secretion in an autocrine style has reportedly contributed to cancer progression in various types of malignancies including hepatocellular carcinoma (HCC).

***Research motivation***

Tumour markers for HCC with a high sensitivity and specificity are necessary.

***Research objectives***

We aimed to estimate the serum FGF-19 concentrations in HCC cases and assess the diagnostic performance of FGF-19 for the detection of HCC.

***Research methods***

We recruited 90 adult participants and divided them into three equal groups: Healthy controls, cirrhosis patients, and HCC patients. Serum FGF-19 concentrations were measured using the Human FGF-19 ELISA kit.

***Research results***

We detected a high statistically significant difference in the FGF-19 levels between the three groups, with the highest level occurring in the HCC group, followed by the cirrhosis and control groups (236.44 ± 40.94 *vs* 125.63 ± 31.54 *vs* 69.60 ± 20.90 pg/mL, respectively, *P* ≤ 0.001). For the detection of HCC, ROC curve analysis showed that FGF-19 produced a better diagnostic performance than alpha fetoprotein with an AUC of 0.98 *vs* 0.78.

***Research conclusions***

FGF-19 may be a possible novel non-invasive marker for HCC.

***Research perspectives***

FGF-19 could serve as a predictor of prognosis and a marker for follow-up after HCC treatment. Furthermore, the FGF-19 pathway may be a therapeutic target for the management of HCC.

**REFERENCES**

1 **Rysz J**, Gluba-Brzózka A, Mikhailidis DP, Banach M. Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease. *Expert Opin Investig Drugs* 2015; **24**: 603-610 [DOI: 10.1517/13543784.2015.1006357]

2 **Zhang J**, Li H, Bai N, Xu Y, Song Q, Zhang L, Wu G, Chen S, Hou X, Wang C, Wei L, Xu A, Fang Q, Jia W. Decrease of FGF19 contributes to the increase of fasting glucose in human in an insulin-independent manner. *J Endocrinol Invest* 2019; **42**: 1019-1027 [PMID: 30852757 DOI: 10.1007/s40618-019-01018-5]

3 **Babaknejad N**, Nayeri H, Hemmati R, Bahrami S, Esmaillzadeh A. An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity. *Horm Metab Res* 2018; **50**: 441-452 [DOI:10.1055/a-0623-2909]

4 **Gómez-Ambrosi J**, Gallego-Escuredo JM, Catalán V, Rodríguez A, Domingo P, Moncada R, Valentí V, Salvador J, Giralt M, Villarroya F, Frühbeck G. FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss. *Clin Nutr* 2017; **36**: 861-868 [PMID: 27188262 DOI: 10.1016/j.clnu.2016.04.027]

5 **Repana D**, Ross P. Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. *Diseases* 2015; **3**: 294-305 [PMID: 28943626 DOI: 10.3390/diseases3040294]

6 **Shimokawa T**, Furukawa Y, Sakai M, Li M, Miwa N, Lin YM, Nakamura Y. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex. *Cancer Res* 2003; **63**: 6116-6120 [PMID: 14559787]

7 **Zaharieva BM**, Simon R, Diener PA, Ackermann D, Maurer R, Alund G, Knönagel H, Rist M, Wilber K, Hering F, Schönenberger A, Flury R, Jäger P, Fehr JL, Mihatsch MJ, Gasser T, Sauter G, Toncheva DI. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. *J Pathol* 2003; **201**: 603-608 [PMID: 14648664 DOI: 10.1002/path.1481]

8 **Gowardhan B**, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN, Leung HY. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. *Br J Cancer* 2005; **92**: 320-327 [PMID: 15655558 DOI: 10.1038/sj.bjc.6602274]

9 **Ruohola JK**, Viitanen TP, Valve EM, Seppänen JA, Loponen NT, Keskitalo JJ, Lakkakorpi PT, Härkönen PL. Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. *Cancer Res* 2001; **61**: 4229-4237 [PMID: 11358849]

10 **Zhang JH**, Nolan JD, Kennie SL, Johnston IM, Dew T, Dixon PH, Williamson C, Walters JR. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. *Am J Physiol Gastrointest Liver Physiol* 2013; **304**: G940-G948 [PMID: 23518683 DOI: 10.1152/ajpgi.00398.2012]

11 **Kong B**, Wang L, Chiang JY, Zhang Y, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. *Hepatology* 2012; **56**: 1034-1043 [PMID: 22467244 DOI: 10.1002/hep.25740]

12 **Maeda T**, Kanzaki H, Chiba T, Ao J, Kanayama K, Maruta S, Kusakabe Y, Saito T, Kobayashi K, Kiyono S, Nakamura M, Ogasawara S, Suzuki E, Ooka Y, Nakamoto S, Nakagawa R, Muroyama R, Kanda T, Maruyama H, Kato N. Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma. *BMC Cancer* 2019; **19**: 1088 [PMID: 31718608 DOI: 10.1186/s12885-019-6322-9]

13 **Lin ZZ**, Hsu C, Jeng YM, Hu FC, Pan HW, Wu YM, Hsu HC, Hu MC, Cheng AL. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma. *Liver Int* 2019; **39**: 1682-1691 [PMID: 30698907]

14 **Johansson H**, Mörk LM, Li M, Sandblom AL, Björkhem I, Höijer J, Ericzon BG, Jorns C, Gilg S, Sparrelid E, Isaksson B, Nowak G, Ellis E. Circulating Fibroblast Growth Factor 19 in Portal and Systemic Blood. *J Clin Exp Hepatol* 2018; **8**: 162-168 [PMID: 29892179 DOI: 10.1016/j.jceh.2017.07.001]

15 **Gao L**, Lv G, Li R, Liu WT, Zong C, Ye F, Li XY, Yang X, Jiang JH, Hou XJ, Jing YY, Han ZP, Wei LX. Glycochenodeoxycholate promotes hepatocellular carcinoma invasion and migration by AMPK/mTOR dependent autophagy activation. *Cancer Lett* 2019; **454**: 215-223 [PMID: 30980867 DOI: 10.1016/j.canlet.2019.04.009]

16 **Degirolamo C**, Modica S, Vacca M, Di Tullio G, Morgano A, D'Orazio A, Kannisto K, Parini P, Moschetta A. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. *Hepatology* 2015; **61**: 161-170 [PMID: 24954587 DOI: 10.1002/hep.27274]

17 **Kong B**, Huang J, Zhu Y, Li G, Williams J, Shen S, Aleksunes LM, Richardson JR, Apte U, Rudnick DA, Guo GL. Fibroblast growth factor 15 deficiency impairs liver regeneration in mice. *Am J Physiol Gastrointest Liver Physiol* 2014; **306**: G893-G902 [PMID: 24699334 DOI: 10.1152/ajpgi.00337.2013]

18 **Uriarte I**, Fernandez-Barrena MG, Monte MJ, Latasa MU, Chang HC, Carotti S, Vespasiani-Gentilucci U, Morini S, Vicente E, Concepcion AR, Medina JF, Marin JJ, Berasain C, Prieto J, Avila MA. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. *Gut* 2013; **62**: 899-910 [PMID: 23292666 DOI: 10.1136/gutjnl-2012-302945]

19 **Teng Y**, Zhao H, Gao L, Zhang W, Shull AY, Shay C. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling. *Cancer Res* 2017; **77**: 6215-6225 [PMID: 28951455 DOI: 10.1158/0008-5472.CAN-17-2039]

20 **Kang HJ**, Haq F, Sung CO, Choi J, Hong SM, Eo SH, Jeong HJ, Shin J, Shim JH, Lee HC, An J, Kim MJ, Kim KP, Ahn SM, Yu E. Characterization of Hepatocellular Carcinoma Patients with *FGF19* Amplification Assessed by Fluorescence in situ Hybridization: A Large Cohort Study. *Liver Cancer* 2019; **8**: 12-23 [PMID: 30815392 DOI: 10.1159/000488541]

21 **Cui G**, Martin RC, Jin H, Liu X, Pandit H, Zhao H, Cai L, Zhang P, Li W, Li Y. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver. *J Exp Clin Cancer Res* 2018; **37**: 136 [PMID: 29973237 DOI: 10.1186/s13046-018-0781-8]

22 **Zhao H**, Lv F, Liang G, Huang X, Wu G, Zhang W, Yu L, Shi L, Teng Y. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation. *Oncotarget* 2016; **7**: 13575-13586 [PMID: 26498355 DOI: 10.18632/oncotarget.6185]

23 **Chan AW**, Tong JH, Chan SL, Lai PB, To KF. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. *Histopathology* 2014; **64**: 935-950 [PMID: 24506513 DOI: 10.1111/his.12342]

24 **Li Y**, Zhang W, Doughtie A, Cui G, Li X, Pandit H, Yang Y, Li S, Martin R. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma. *Oncotarget* 2016; **7**: 52329-52339 [PMID: 27447573 DOI: 10.18632/oncotarget.10750]

25 **Hagel M**, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim JL, Hodous B, Brooijmans N, Shutes A, Winter C, Lengauer C, Kohl NE, Guzi T. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. *Cancer Discov* 2015; **5**: 424-437 [PMID: 25776529 DOI: 10.1158/2159-8290.CD-14-1029]

26 **Koelfat KV**, Bloemen JG, Jansen PL, Dejong CH, Schaap FG, Olde Damink SW. The portal-drained viscera release fibroblast growth factor 19 in humans. *Physiol Rep* 2016; **4** [PMID: 28003563 DOI: 10.14814/phy2.13037]

27 **Heidelbaugh JJ**, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. *Am Fam Physician* 2006; **74**: 756-762 [PMID: 16970019]

28 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018; **69**: 182-236 [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019]

29 **Ferlay J**, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; **136**: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]

30 **Aboelfotoh AO**, Foda EM, Elghandour AM, Teama NM, Abouzein RA, Mohamed GA. Talin-1; other than a potential marker for hepatocellular carcinoma diagnosis. *Arab J Gastroenterol* 2020; **21**: 80-84 [PMID: 32439236 DOI: 10.1016/j.ajg.2020.04.017]

31 **Heimbach JK**, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology* 2018; **67**: 358-380 [PMID: 28130846 DOI: 10.1002/hep.29086]

32 **Toyoda H**, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. *Liver Cancer* 2015; **4**: 126-136 [PMID: 26020034 DOI: 10.1159/000367735]

33 **Sun Y**, Zhu M, Zhao H, Ni X, Chang R, Su J, Huang H, Cui S, Wang X, Yuan J, Yuan J, OuYang R, Zhang R, Chen W, Gu Y, Sun Y. Serum Fibroblast Growth Factor 19 and Total Bile Acid Concentrations Are Potential Biomarkers of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus. *Biomed Res Int* 2020; **2020**: 1751989 [PMID: 32104677 DOI: 10.1155/2020/1751989]

34 **Wunsch E**, Milkiewicz M, Wasik U, Trottier J, Kempińska-Podhorodecka A, Elias E, Barbier O, Milkiewicz P. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease. *Sci Rep* 2015; **5**: 13462 [PMID: 26293907 DOI: 10.1038/srep13462]

35 **Hirschfield GM**, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC Jr, Parés A, Trauner M, Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelloe E, Böhm O, Shapiro D. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. *Gastroenterology* 2015; **148**: 751-61.e8 [PMID: 25500425 DOI: 10.1053/j.gastro.2014.12.005]

36 **Neuschwander-Tetri BA**, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *Lancet* 2015; **385**: 956-965 [PMID: 25468160 DOI: 10.1016/S0140-6736(14)61933-4]

37 **Chae YK**, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. *Oncotarget* 2017; **8**: 16052-16074 [PMID: 28030802 DOI: 10.18632/oncotarget.14109]

38 **Zheng N**, Wei W, Wang Z. Emerging roles of FGF signaling in hepatocellular carcinoma. *Transl Cancer Res* 2016; **5**: 1-6 [PMID: 27226954]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the institutional review board of Faculty of Medicine, Ain Shams University, Cairo, Egypt.

**Informed consent statement:** Informed consent was obtained from every participant before the enrollment into the study.

**Conflict-of-interest statement:** All authors have nothing to disclose.

**Data sharing statement:** The statistical code and dataset are available from the corresponding author at [ghadaabdelrahman@med.asu.edu.eg](mailto:ghadaabdelrahman@med.asu.edu.eg). The participants gave informed consent for the data sharing.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 19, 2021

**First decision:** December 3, 2021

**Article in press:** February 20, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Egypt

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Kanno H, Tong GD **S-Editor:** Ma YJ **L-Editor:** Wang TQ **P-Editor:** Ma YJ


**Figure Legends**



**Figure 1** **Serum fibroblast growth factor 19 levels in the control, cirrhosis, and hepatocellular carcinoma groups.** FGF-19: Fibroblast growth factor 19; HCC: Hepatocellular carcinoma.



**Figure 2 Correlation between serum fibroblast growth factor 19 and alpha fetoprotein.** AFP: Alpha fetoprotein; FGF-19: Fibroblast growth factor 19.



**Figure 3 Receiver operating characteristic curves for assessing the diagnostic performance of FGF-19 and alpha fetoprotein for the differentiation of HCC cases.** AFP: Alpha fetoprotein; FGF-19: Fibroblast growth factor 19.

**Table 1 Characteristics of all participants**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | | **Control (*n* = 30)** | **Cirrhosis (*n* = 30)** | **HCC (*n* = 30)** | ***P* value** | ***Post-hoc* analysis** |
| Age (yr) | | 51.07 ± 12.38 | 53.57 ± 10.48 | 57.37 ± 10.25 | 0.091 |  |
| Sex | Female | 12 (40%) | 10 (33.3%) | 11 (36.7%) | 0.866 |  |
| Male | 18 (60%) | 20 (66.7%) | 19 (63.3%) |
| Aetiology of hepatic disease | |  | HCV (*n* = 18, 60%) | HCV (*n* = 25, 83.33%) | 0.691 |  |
| HBV (*n* = 7, 23.3%) | HBV (*n* = 3, 10%) |
| Others (*n* = 5, 16.6%) | Others (*n* = 2, 6.66%) |
| Child-Pugh Class | Class A |  | 18 (60%) | 5 (16.7%) | 0.002 |  |
| Class B | 6 (20%) | 11 (36.7%) |
| Class C | 6 (20%) | 14 (46.7%) |
| Fibroblast growth factor 19 (pg/mL) | | 69.60 ± 20.90 | 125.63 ± 31.54 | 236.44 ± 40.94 | ≤ 0.001 | P1 ≤ 0.001 |
| P2 ≤ 0.001 |
| P3 ≤ 0.001 |
| Alpha fetoprotein (ng/mL) | | 3.35 (2.5 – 4.5) | 6.4 (4 – 6.9) | 513.5 (5.6 – 1500) | ≤ 0.001 | P1 ≤ 0.001 |
| P2 ≤ 0.001 |
| P3 ≤ 0.001 |
| Haemoglobin (g/dL) | | 13.16 ± 1.24 | 10.68 ± 1.11 | 10.49 ± 1.59 | ≤ 0.001 | P1 ≤ 0.001 |
| P2 ≤ 0.001 |
| P3 = 0.588 |
| White blood cells (109/L) | | 7.09 ± 2.01 | 6.37 ± 2.27 | 5.86 ± 2.43 | 0.109 |  |
| Platelets (109/L) | | 288.10 ± 92.79 | 144.17 ± 48.27 | 136.13 ± 43.78 | ≤ 0.001 | P1 ≤ 0.001 |
| P2 ≤ 0.001 |
| P3 = 0.636 |
| Alanine aminotransferase (U/L) | | 20.67 ± 7.02 | 65.47 ± 33.00 | 52.97 ± 23.25 | ≤ 0.001 | P1 ≤ 0.001 |
| P2 ≤ 0.001 |
| P3 = 0.044 |
| Aspartate aminotransferase (U/L) | | 23.23 ± 12.69 | 49.87 ± 24.78 | 45.93 ± 20.02 | ≤ 0.001 | P1 ≤ 0.001 |
| P2 ≤ 0.001 |
| P3 = 0.444 |
| Creatinine (mg/dL) | | 0.90 ± 0.22 | 0.99 ± 0.36 | 1.11 ± 0.51 | 0.112 |  |
| Urea (mg/dL) | | 21.70 ± 7.37 | 30.10 ± 18.82 | 32.97 ± 25.17 | 0.057 |  |
| Albumin (g/dL) | | 3.96 ± 0.34 | 3.33 ± 0.53 | 2.65 ± 0.43 | ≤ 0.001 | P1 ≤ 0.001 |
| P2 ≤ 0.001 |
| P3 ≤ 0.001 |
| INR | | 1.09 ± 0.11 | 1.54 ± 0.24 | 1.85 ± 0.36 | ≤ 0.001 | P1 ≤ 0.001 |
| P2 ≤ 0.001 |
| P3 ≤ 0.001 |
| Bilirubin (mg/dL) | | 0.75 ± 0.26 | 1.80 ± 0.74 | 1.97 ± 0.42 | ≤ 0.001 | P1 ≤ 0.001 |
| P2 ≤ 0.001 |
| P3 = 0.211 |
| Fasting blood glucose (µmoI/L) | | 5.19 ± 0.19 | 4.46 ± 0.28 | 4.46 ± 0.28 | ≤ 0.001 | P1 ≤ 0.001 |
| P2 ≤ 0.001 |
| P3 = 1.000 |

HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; INR: International normalised ratio.

**Table 2 Serum fibroblast growth factor 19 levels in the cirrhosis and hepatocellular carcinoma groups according to Child-Pugh score**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Child-Pugh Class** | **Cirrhosis** (***n* =** 30) | **HCC** (***n* =** 30) |
| Fibroblast growth factor 19 (pg/mL) | Class A | 129.311 (± 38.01) | 223.320 (± 37.39) |
| Class B | 123.383 (± 21.51) | 230.209 (± 30.96) |
| Class C | 116.833 (± 15.69) | 246.029 (± 48.71) |
|  | *P* value | 0.7046 | 0.479 |

HCC: Hepatocellular carcinoma.

**Table 3 Tumour characteristics of hepatocellular carcinoma cases**

|  |  |  |
| --- | --- | --- |
|  | | **HCC (*n* = 30)** |
| Size | < 2 cm | 3 (10%) |
| 2-3 cm | 17 (56.7%) |
| > 5 cm | 10 (33.3%) |
| Number of tumour foci | Single | 10 (33.3%) |
| 2-3 | 9 (30%) |
| Multiple | 11 (36.7%) |
| Portal vein thrombosis | No | 21 (70%) |
| Yes | 9 (30%) |
| Metastasis | No | 27 |
| Yes | 3 |

HCC: Hepatocellular carcinoma.

**Table 4 Serum fibroblast growth factor 19 levels according to variables in the hepatocellular carcinoma group**

|  |  |  |  |
| --- | --- | --- | --- |
|  | | **FGF-19 pg/mL (mean ± SD)** | ***P* value** |
| Size | < 2 cm | 219.9 ± 51.79 | 0.254 |
| 2-3 cm | 229.2 ± 36.06 |
| > 5 cm | 253.72 ± 44.39 |
| Number | Single | 234.17 ± 36.38 | 0.885 |
| 2 - 3 | 242.28 ± 45.69 |
| Multiple | 233.74 ± 44.22 |
| Portal vein thrombosis | No | 230.55 ± 39.13 | 0.235 |
| Yes | 250.2 ± 44.08 |
| Right upper quadrant pain | No | 237.171 ± 41.026 | 0.885 |
| Yes | 234.744 ± 43.163 |
| Weight loss | No | 229.132 ± 34.285 | 0.106 |
| Yes | 256.550 ± 52.793 |
| Pruritus | No | 239.518 ± 39.170 | 0.505 |
| Yes | 227.988 ± 47.214 |
| Jaundice | No | 226.182 ± 29.468 | 0.118 |
| Yes | 249.86 ± 50.48 |
| Fever | No | 237.668 ± 40.531 | 0.834 |
| Yes | 234.33 ± 43.54 |
| Oedema | No | 228.945 ± 37.054 | 0.16 |
| Yes | 251.44 ± 46.12 |

FGF-19: Fibroblast growth factor 19.

**Table 5 Correlation between fibroblast growth factor 19 and alpha fetoprotein with patients’ laboratory data**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **AFP** | | **FGF-19** | |
| ***r*** | ***P* value** | ***r*** | ***P* value** |
| AFP | – | – | 0.383 | 0.003 |
| FGF-19 | 0.383 | 0.003 | – | – |
| Age | 0.062 | 0.640 | 0.125 | 0.343 |
| Haemoglobin | -0.196 | 0.133 | -0.060 | 0.651 |
| White blood cells | -0.064 | 0.627 | -0.144 | 0.272 |
| Platelets | 0.018 | 0.893 | -0.151 | 0.248 |
| Alanine aminotransferase | 0.036 | 0.786 | -0.151 | 0.249 |
| Aspartate aminotransferase | 0.040 | 0.764 | -0.024 | 0.855 |
| Creatinine | -0.164 | 0.211 | 0.093 | 0.480 |
| Urea | -0.022 | 0.867 | 0.012 | 0.929 |
| Albumin | -0.213 | 0.102 | -0.500 | 0.000 |
| INR | -0.001 | 0.993 | 0.357 | 0.005 |
| Bilirubin | -0.093 | 0.479 | 0.008 | 0.952 |
| Fasting blood glucose | -0.135 | 0.477 | 0.056 | 0.767 |

AFP: Alpha fetoprotein; FGF-19: Fibroblast growth factor 19; INR: International normalised ratio.

**Table 6 Diagnostic performance of** **fibroblast growth factor 19 and alpha fetoprotein for differentiation of hepatocellular carcinoma cases**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Cut-off point** | **AUC** | **Sensitivity** | **Specificity** | **PPV** | **NPV** |
| FGF-19 | > 180 pg/mL | 0.98 | 100% | 90% | 90% | 100% |
| AFP | > 8.2 ng/mL | 0.78 | 63.33% | 83.33% | 79.2% | 69.4% |

AFP: Alpha fetoprotein; AUC: Area under the curve; FGF-19: Fibroblast growth factor 19; HCC: Hepatocellular carcinoma; NPV: Negative predictive value; PPV: Positive predictive value.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**